Table 4.
Work Productivity and Activity Impairment Questionnaire - Rheumatoid Arthritis (WPAI-RA): mean presenteeism, absenteeism, and work productivity loss at baseline and least-squares mean change from baseline at week 24 and at week 52 among patients employed at baseline and at Week 24 or Week 52
| WPAI-RA questions administered to patients who were employeda | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline, Mean (SD) | Week 24, LSM (95% CI) | Week 52, LSM (95% CI) | |||||||
| MTX (N = 210) | Baricitinib 4 mg (N = 159) | Baricitinib 4 mg + MTX (N = 215) | MTX (n = 85) | Baricitinib 4 mg (n = 63) | Baricitinib 4 mg + MTX (n = 105) | MTX (n = 67) | Baricitinib 4 mg (n = 58) | Baricitinib 4 mg + MTX (n = 96) | |
| Percent employed at time pointb, n (%) | 94 (45) | 67 (42) | 117 (55) | 80 (94) | 59 (94) | 94 (90) | 57 (85) | 55 (95) | 80 (83) |
| Percent impairment while working due to RA (presenteeism) | 49 (28) | 49 (26) | 50 (26) | − 20 (− 25, − 15) | − 29 (− 35, − 24)* | − 31 (− 35, − 26)** | − 26 (− 31, − 20) | − 29 (− 35, − 23) | − 31 (− 35, − 27) |
| Percent overall work impairment due to RA (work productivity loss) | 53 (29) | 51 (27) | 55 (27) | − 18 (− 24, − 13) | − 29 (− 36, − 23)* | − 30 (− 35, − 25)** | − 23 (− 30, − 17) | − 30 (− 37 − 23) | − 32 (− 38, − 27)* |
| Percent work time missed due to RA (absenteeism) | 19 (31) | 14 (29) | 15 (25) | − 2 (− 7, 2) | − 10 (− 15, − 5)* | − 9 (− 12, − 5)* | − 3 (− 7, 1) | − 8 (− 12, − 3) | − 8 (− 11, − 4) |
CI confidence interval, LSM least-squares mean, MTX methotrexate, RA rheumatoid arthritis
aData are presented as mean (standard deviation) or LSM (95% CI)
bFor weeks 24 and 52, the percentage of patients employed at baseline and who continued to be employed at that time point
*p ≤ 0.05; **p ≤ 0.01 vs. MTX